Patents by Inventor Anna Secher

Anna Secher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for treating Alzheimer's disease using semaglutide
    Patent number: 12539326
    Abstract: The present invention relates to improved medical therapies for all forms and stages of dementia involving administration of (i) GLP-1 receptor agonists to subjects with metabolic syndrome or (ii) semaglutide.
    Type: Grant
    Filed: December 12, 2024
    Date of Patent: February 3, 2026
    Assignee: Novo Nordisk A/S
    Inventors: Charlotte Christine Thim Hansen, Lotte Bjerre Knudsen, Anna Secher, Daniél Vega Møller
  • GLP-1 RECEPTOR AGONISTS IN DEMENTIA
    Publication number: 20250099549
    Abstract: The present invention relates to improved medical therapies for all forms and stages of dementia involving administration of (i) GLP-1 receptor agonists to subjects with metabolic syndrome or (ii) semaglutide.
    Type: Application
    Filed: December 12, 2024
    Publication date: March 27, 2025
    Applicant: Novo Nordisk A/S
    Inventors: Sarah Friedrich, Charlotte Christine Thim Hansen, Lotte Bjerre Knudsen, Anna Secher
  • GLP-1 RECEPTOR AGONISTS IN DEMENTIA
    Publication number: 20240207364
    Abstract: The present invention relates to improved medical therapies for all forms and stages of dementia involving administration of (i) GLP-1 receptor agonists to subjects with metabolic syndrome or (ii) semaglutide.
    Type: Application
    Filed: January 30, 2024
    Publication date: June 27, 2024
    Inventors: Sarah Friedrich, Charlotte Christine Thim Hansen, Lotte Bjerre Knudsen, Anna Secher
  • GLP-1 RECEPTOR AGONISTS IN DEMENTIA
    Publication number: 20230302094
    Abstract: The present invention relates to improved medical therapies for all forms and stages of dementia involving administration of (i) GLP-1 receptor agonists to subjects with metabolic syndrome or (ii) semaglutide.
    Type: Application
    Filed: June 12, 2023
    Publication date: September 28, 2023
    Applicant: Novo Nordisk A/S
    Inventors: Sarah Friedrich, Charlotte Christine Thim Hansen, Lotte Bjerre Knudsen, Anna Secher
  • Compounds for treatment of obesity
    Patent number: 11753455
    Abstract: The invention relates to a construct comprising a compound targeting areas in the brain involved in the regulation of body weight and an allosteric ligand to a receptor located in the blood-brain barrier (BBB). The invention also relates to compositions and uses of such construct, for example in the prevention or treatment of overweight and obesity. Preferred compounds for regulation of body weight include GLP-1 receptor agonists (GLP-1RA), and preferred receptors located in the BBB include the transferrin receptor (TfR). Exemplary fusions and conjugates of GLP-1 RA's and anti TfR-Fab's exhibit an increased binding to brain regions expressing the GLP-1 receptor as compared to fusions or conjugates with inactive control Fab's, in particular in brain areas protected by the BBB. In vivo mice studies confirm increased reduction in food intake as well as weight loss for the active construct compared to the inactive one.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: September 12, 2023
    Assignee: Novo Nordisk A/S
    Inventors: Nikolaj Kulahin Roed, Michael Paolo Bastner Sandrini, Jesper Lau, Paw Bloch, Anna Secher, Adam Paul Chambers, Jim McGuire, Lotte Bjerre Knudsen
  • GLP-1 RECEPTOR AGONISTS IN DEMENTIA
    Publication number: 20220280612
    Abstract: The present invention relates to improved medical therapies for all forms and stages of dementia involving administration of (i) GLP-1 receptor agonists to subjects with metabolic syndrome or (ii) semaglutide.
    Type: Application
    Filed: May 4, 2022
    Publication date: September 8, 2022
    Inventors: Sarah Friedrich, Charlotte Christine Thim Hansen, Lotte Bjerre Knudsen, Anna Secher
  • NOVEL COMPOUNDS FOR TREATMENT OF OBESITY
    Publication number: 20210261641
    Abstract: The invention relates to a construct comprising a compound targeting areas in the brain involved in the regulation of body weight and an allosteric ligand to a receptor located in the blood-brain barrier (BBB). The invention also relates to compositions and uses of such construct, for example in the prevention or treatment of overweight and obesity. Preferred compounds for regulation of body weight include GLP-1 receptor agonists (GLP-1RA), and preferred receptors located in the BBB include the transferrin receptor (TfR). Exemplary fusions and conjugates of GLP-1 RA's and anti TfR-Fab's exhibit an increased binding to brain regions expressing the GLP-1 receptor as compared to fusions or conjugates with inactive control Fab's, in particular in brain areas protected by the BBB. In vivo mice studies confirm increased reduction in food intake as well as weight loss for the active construct compared to the inactive one.
    Type: Application
    Filed: June 20, 2019
    Publication date: August 26, 2021
    Inventors: Nikolaj Kulahin Roed, Michael Paolo Bastner Sandrini, Jesper Lau, Paw Bloch, Anna Secher, Adam Paul Chambers, Jim McGuire, Lotte Bjerre Knudsen